Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion type Assertion NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_head.
- NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion description "[Over the last few years, excitement over this class of agents has escalated due to reported activity as single agent in BRCA1- or BRCA2-associated ovarian or breast cancers, and in combination with chemotherapy in triple negative breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_provenance.
- NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion evidence source_evidence_literature NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_provenance.
- NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion SIO_000772 21718592 NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_provenance.
- NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion wasDerivedFrom befree-2016 NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_provenance.
- NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_assertion wasGeneratedBy ECO_0000203 NP906165.RAauDeLtUhE9EZbVJM7nUouVChNF8Mtpqhy1Ipqnv91Dk130_provenance.